UGT2B17 and UGT2B28 germline deletions and differential expression have been associated with a number of clinical conditions such as risk and progression of prostate cancer (PCa), but also leukaemia, oesophageal, colorectal, lung, bladder and breast cancers [9–14]. This evidence concerns the gene UGT2B28 and prostate cancer.